Evidence map›Paper›PMID 36818338›Full record

ArticleFrontiers in cardiovascular medicine2023

Cardiac magnetic resonance outperforms echocardiography to predict subsequent implantable cardioverter defibrillator therapies in ST-segment elevation myocardial infarction patients.

Víctor Marcos-Garcés, Nerea Perez, Jose Gavara, Maria P Lopez-Lereu, Jose V Monmeneu, Cesar Rios-Navarro, Elena de Dios, Hector Merenciano-González, Ana Gabaldon-Pérez, Ángel Ferrero-De-Loma-Osorio and 9 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Víctor Marcos-GarcésDepartment of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Nerea PerezINCLIVA Health Research Institute, Valencia, Spain.
Jose GavaraINCLIVA Health Research Institute, Valencia, Spain.
Maria P Lopez-LereuCardiovascular Magnetic Resonance Unit, ASCIRES Biomedical Group, Valencia, Spain.
Jose V MonmeneuCardiovascular Magnetic Resonance Unit, ASCIRES Biomedical Group, Valencia, Spain.
Cesar Rios-NavarroINCLIVA Health Research Institute, Valencia, Spain.
Elena de DiosFaculty of Medicine and Odontology, University of Valencia, Valencia, Spain.
Hector Merenciano-GonzálezDepartment of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Ana Gabaldon-PérezDepartment of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Ángel Ferrero-De-Loma-OsorioDepartment of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Ángel Martínez-BrotonsDepartment of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Lourdes BondanzaDepartment of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Juan Miguel Sánchez-GómezDepartment of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Cristina AlbiachDepartment of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Julio NunezDepartment of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Antoni Bayés-GenísCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Francisco J ChorroDepartment of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Ricardo Ruiz-GranellDepartment of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Vicente BodiDepartment of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Hospital Clínico Universitario de Valencia · ESINCLIVA Health Research Institute · ESCentro de Investigación Biomédica en Red · ESUniversitat de València · ESUniversitat Politècnica de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Implantable cardioverter defibrillators (ICD) are effective as a primary prevention measure of ventricular tachyarrhythmias in patients with ST-segment elevation myocardial infarction (STEMI) and depressed left ventricular ejection fraction (LVEF). The implications of using cardiac magnetic resonance (CMR) instead of echocardiography (Echo) to assess LVEF prior to the indication of ICD in this setting are unknown. Materials and methods: We evaluated 52 STEMI patients (56.6 ± 11 years, 88.5% male) treated with ICD in primary prevention who underwent echocardiography and CMR prior to ICD implantation. ICD implantation was indicated based on the presence of heart failure and depressed LVEF (≤ 35%) by echocardiography, CMR, or both. Prediction of ICD therapies (ICD-T) during follow-up by echocardiography and CMR before ICD implantation was assessed. Results: Compared to echocardiography, LVEF was lower by cardiac CMR (30.2 ± 9% vs. 37.4 ± 7.6%, Conclusion: In STEMI patients treated with ICD, assessment of LVEF by CMR outperforms Echo-LVEF to predict the subsequent use of appropriate ICD therapies.

Indexed as

cardiac magnetic resonanceimplantable cardioverter-defibrillatorleft ventricular ejection fractionmyocardial infarctionventricular tachyarrhythmias

Identifiers

PMID36818338
PMCPMC9937054
OpenAlexW4319161921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.